-
Ascentage Pharma’s Olverembatinib Receives Third BTD in China for Ph+ ALL Treatment
•
China-based Ascentage Pharma (HKG: 6855) has announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has awarded Breakthrough Therapy Designation (BTD) to its olverembatinib, a novel BCR-ABL1 tyrosine kinase inhibitor (TKI). The designation is for the drug’s use in combination with low-intensity chemotherapy as…
-
ImmuneOnco’s Timdarpacept (IMM01) and IMM2510 Receive NMPA Approval for Clinical Study in Advanced Malignant Tumors
•
China-based ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541) has received approval from the National Medical Products Administration (NMPA) to commence a clinical study for its novel therapeutic combination. The study will evaluate timdarpacept (IMM01), an SIRPαFc fusion protein, in combination with IMM2510, a PD-L1/VEGF bispecific antibody (BsAb), with or without chemotherapy,…
-
CSPC Pharma’s JMT108 Receives NMPA Clinical Approval for Advanced Malignant Tumors
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced clinical approval from the National Medical Products Administration (NMPA) for JMT108, an anti-PD-1/IL-15 bi-functional fusion protein. The targeted indication for this novel therapy is advanced malignant tumors, marking a significant step forward in the development of innovative cancer treatments in China.…
-
Sandoz’s Q4 2024 Results Show Strong Biosimilar Growth
•
Switzerland-headquartered Sandoz (SWX: SDZ) has released its Q4 2024 financial results. The firm’s global revenues rose 9% year-on-year (YOY) in constant currencies to USD 10.7 billion during the year. The firm’s performance improved during the year, with Q4 revenues up 9% YOY to USD 2.7 billion. Sales BreakdownGeneric drugs generated…
-
Peijia Medical Completes First Two Implants of Trilogy THV System in Taiwan
•
China’s Peijia Medical Ltd (HKG: 9996) announced the completion of the first two implant surgeries using its Trilogy transcatheter heart valve (THV) System for the treatment of severe aortic valve regurgitation in Taiwan. Product DetailsThe Trilogy THV System, a proprietary transcatheter aortic valve replacement product with CE mark, is designed…
-
Huadong Medicine’s V30 Optical Radiofrequency Device Receives NMPA Review Approval
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that the National Medical Products Administration (NMPA) has accepted a market filing for it’s subsidiary Viora Ltd.’s V30 optical radiofrequency therapy device. The Category III medical device is used for various medical aesthetics procedures, including skin tightening, hair removal, and treating vascular…
-
Jiangsu Nhwa Pharmaceutical Invests in NeuroThree to Develop CNS Therapies
•
China-based Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262) announced plans to subscribe to Hong Kong-headquartered NeuroThree Therapeutics, Inc.’s Pre-Series A financing round, investing USD 3.5 million for 12.5 million shares. Upon completion of the transaction, Nhwa will hold a 10.448% stake in NeuroThree. Company BackgroundFounded in 2021, NeuroThree focuses on…
-
Bayer Posts Steady Q4 Growth, Pharmaceutical Sales Lead the Way
•
German giant Bayer (ETR: BAYN) has released its Q4 2024 financial results, reporting a 0.7% year-on-year (YOY) growth in constant currency terms, with global group sales for the twelve months reaching EUR 46.6 billion (USD 50.3 billion). Sales Performance by DivisionCrop Sciences sales declined by 2% to EUR 22.2 billion…
-
NovoCare Pharmacy Offers Reduced-Cost Wegovy for Cash-Paying Patients
•
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced the launch of NovoCare Pharmacy, a direct-to-patient delivery option designed to provide cash-paying patients with all dose strengths of Wegovy at a reduced cost of USD 499 per month. Program DetailsThe introduction of NovoCare Pharmacy mirrors the approach taken by US major…
-
Antengene’s Xpovio Receives Marketing Approval in Indonesia
•
China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced receiving marketing approval in Indonesia for its Xpovio (selinexor). The approval grants the drug three indications in the Southeast Asian country. Indications ApprovedThe drug is approved for: Drug BackgroundXpovio, the world’s first and only FDA-approved oral XPO1 inhibitor, was discovered by US-based…
-
Sino Medical Sciences’ HT Supreme Stent System Gains Vietnamese Marketing Approval
•
China-based Sino Medical Sciences Technology Inc., (SHA: 688108) announced that it has received marketing approval from the Ministry of Health of Vietnam for its HT Supreme drug-eluting stent system. The approval allows the product to be used to improve the diameter of the coronary artery lumen in symptomatic heart disease…
-
Yifan Pharma Secures Rights to Bayer’s Stivarga and Nexavar in China
•
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced a commercialization agreement with Bayer (ETR: BAYN), securing exclusive rights to promote the German company’s Stivarga (regorafenib) and Nexavar (sorafenib) in mainland China. Yifan Pharma’s PortfolioYifan Pharma has a team of 300 specialists in oncology marketing and sales. Its product lineup includes…
-
RongCan Biotech’s mRNA HPV Vaccine Receives FDA Clinical Approval
•
China-based mRNA specialist RongCan (Shanghai) Biotech Co., Ltd announced that it has received clinical approval from the US Food and Drug Administration (FDA) for its mRNA-based human papillomavirus (HPV) therapeutic vaccine. Clinical Approval and SignificanceThis approval marks a significant step forward in the development of therapeutic options for HPV-related conditions.…
-
Insilico Medicine and Tenacia Partner on AI-Driven CNS Therapies
•
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has formed a partnership with compatriot firm Tenacia, a central nervous system (CNS) specialist incubated by Bain Capital. The collaboration aims to integrate Insilico’s cutting-edge generative AI drug discovery platform Pharma AI with Tenacia’s proprietary data assets to develop small molecule inhibitors…
-
Lexenpharm and Sun-Novo Partner on Long-Acting Asthma and COPD Drugs
•
China-based Lexenpharm has formed a partnership with compatriot firm Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) to develop LXP2311 and LXP0531, long-acting drugs targeting asthma and chronic obstructive pulmonary disease (COPD) for the mainland Chinese market. Partnership FocusThe collaboration leverages Lexenpharm’s technical capabilities in respiratory diseases and Sun-Novo’s clinical…
-
Baheal Pharmaceutical Gains Exclusive Rights to Roche’s MabThera in China
•
China-based health services and distribution giant Baheal Pharmaceutical Group (SHE: 301015) last month reached an accord with Roche (SWX: ROG, OTCMKTS: RHHBY), securing exclusive market promotion rights to the Swiss giant’s MabThera (rituximab) in mainland China. Drug ProfileMabThera, the world’s first anti-CD20 monoclonal antibody (mAb), is used to treat Hodgkin…
-
Zhejiang Huahai’s HB0034 Meets Primary Endpoint in GPP Study
•
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that its multi-center, double-blinded, randomized, placebo-parallel controlled pivotal study for HB0034, a Category 1 biologic product for acute generalized pustular psoriasis (GPP), has achieved the primary efficacy endpoint and all secondary efficacy endpoints. Study ResultsGPP is a rare, life-threatening, systemic neutropenic…
-
CStone Pharmaceuticals and SteinCares Ink Licensing Deal for PD-L1 Inhibitor in Latin America
•
China-based CStone Pharmaceuticals (HKG: 2616) and Costa Rica-based drug maker and distributor SteinCares have entered into a licensing agreement. Under the terms of the agreement, SteinCares will obtain exclusive commercialization rights to CStone’s anti-programmed death-ligand 1 (PD-L1) inhibitor sugemalimab (trade name: Cejemly) in the Latin American market, including Brazil, Argentina,…
-
Fosun Pharma’s 24-Valent Pneumococcal Vaccine Receives NMPA Approval for Phase I Trial
•
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd’s (SHA: 600196, HKG: 2196) subsidiary Fosun Adgenvax (Chengdu) Biopharmaceutical Co.,Ltd. is set to commence a Phase I clinical study for its 24-valent pneumococcal polysaccharide conjugate vaccine in China, following clearance from the National Medical Products Administration (NMPA). Vaccine ProfileThe preventative biologic product is…
-
Bio-Thera Solutions Inks Licensing Deal with World Medicine for BAT2206
•
China-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with World Medicine, granting the Turkiye-based firm exclusive distribution and marketing rights to its BAT2206, a biosimilar version of Roche’s Stelara (Ustekinumab). Partnership DetailsUnder the agreement, World Medicine will handle the import, regulatory filing, and sales of the drug…
